Virtus Fund Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Virtus Fund Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$7.94M	Buy	53,002 +20,289	+62%	+$3M	0.08%	198
2017 Q3	$4.97M	Buy	+32,713	New	+$4.92M	0.05%	237
2015 Q1	–	Sell	-275	Closed	-$33K	–	1051
2014 Q4	$33K	Hold	275	–	–	﹤0.01%	871
2014 Q3	$31K	Sell	275 -2,090	-88%	-$199K	﹤0.01%	892
2014 Q2	$224K	Buy	+2,365	New	+$166K	﹤0.01%	934

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Virtus Fund Advisers's VRTX Position: Q4 2017 in Review

Virtus Fund Advisers increased its Vertex Pharmaceuticals (VRTX) stake by 62% in Q4 2017, buying an estimated $3M and bringing the position to 53,002 shares worth $7.94M. The position accounts for 0.08% of the portfolio, ranked #198.

Virtus Fund Advisers first reported a position in VRTX in Q2 2014 and has held it in 5 quarters since. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

Virtus Fund Advisers held 53,002 shares of Vertex Pharmaceuticals worth $7.94M as of Q4 2017.
Virtus Fund Advisers bought 20,289 Vertex Pharmaceuticals shares in Q4 2017, an estimated $3M.
Vertex Pharmaceuticals made up 0.08% of Virtus Fund Advisers's portfolio in Q4 2017, its #198 holding.
Virtus Fund Advisers first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 5 quarters since.
644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.